tRNA for CMT
Charcot-Marie-Tooth (CMT) disease is a common inherited condition that causes progressive muscle weakness, loss of sensation, and disability. CMT disease type 2D, one of the most severe forms of the disease, is caused by mutations that result in dysfunctional glycyl-tRNA synthetase. Millions of CMT patients worldwide currently face limited treatment options that only manage symptoms […]
Dual Tumor Targeting
Immunotherapy using antibodies targeting tumors has led to important clinical advances, yet only 15-20% of all cancer patients respond to immunotherapy. Thus, there is urgent need to increase the efficacy for immunotherapies and enhance anti-tumor responses. This is exemplified by hematological malignancies including diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM), two common and […]
Lumox
Many people with head and neck cancer face harsh treatments like surgery, radiation, or chemotherapy: treatments that often damage speech, swallowing, or appearance. And even then, the cancer sometimes comes back. That can be done better. There is a critical need for therapies that can selectively eliminate tumor cells while preserving healthy tissue. Lumox’s innovative […]
Cell therapy for conjunctival disease
Untreated diseases and damage to the conjunctiva, the thin outer layer covering the white of the eye, pose a serious threat to vision. One common condition is pterygium, where conjunctival tissue grows uncontrollably and extends onto the cornea. The standard treatment involves surgically removing the growth and replacing it with tissue taken from a healthy […]
Antimicrobial Nanoparticles
The problem: Antibiotic resistance is a growing global health threat, causing 1.3 million deaths annually, but no new classes of antibiotics have been developed since 1984. Bacteria combat antibiotics by forming protective biofilms, reducing uptake of antibiotics, enzymatically degrading antibiotics, or actively pumping them out through efflux pumps. Without a new strategy for antibiotics delivery, […]
Next generation formulations for RNA
Liporyx is developing a bioinspired lipid-like polymer technology to safely and specifically deliver nucleic acid therapeutics to diverse cell types in the body. Most RNA therapeutics do not traverse the body well and are typically removed from circulation by the liver, limiting their effectiveness for many diseases. A highly versatile drug delivery system lies at […]
Gelion Care
Diabetic foot ulcers (DFUs) are a common and severe complication of diabetes that affects millions worldwide. DFUs are slow to heal, prone to infections, and often lead to amputations, creating a significant healthcare burden. Existing treatments are costly, inaccessible, or ineffective, and the rising threat of Anti-Microbial Resistance (AMR) further limiting traditional options. At Gelion […]
Macrophage Liposomes
Despite many advancements in cancer treatment, more than 10 million people die each year from cancer worldwide. The most advanced cancer immunotherapy benefits only 10-15% of the treated patients with solid tumors and metastasis. This low response rate is due to suppressed tumor cell-killing immune cells. This suppression is caused by tumour-associated macrophages (TAM), key […]
EV antibodies for the treatment of cancer
Tumour cells communicate with normal cells in the body through special communication bubbles called vesicles. After they reach a healthy cell, this cell is reprogrammed to the benefit of the cancer cell. Until now, no strategies to block these vesicles released by cancer cells have been developed due to lack specific markers and molecules. Recently […]
T-Guard
Philikos is developing T-Guard, an innovative treatment for systemic sclerosis, a severe autoimmune disease where the immune system attacks the body’s own cells and organs. This leads to scar tissue formation that impairs function and, in severe cases, can be fatal. Diffuse cutaneous Systemic Sclerosis (dcSSc) is the most aggressive form, with nearly half of […]